Across TCGA pan-cancer cohorts, TAS2R46 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TAS2R46 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TAS2R46 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAS2R46 expression acts as an unfavorable survival marker.
HNSC and COAD are the cancer types where TAS2R46 Mutation most reproducibly stratifies survival.